pour la recherche uniquement
Réf. CatalogueS1013
| Cibles apparentées | HDAC Caspase Secretase MMP HCV Protease Cysteine Protease DPP Tyrosinase HIV Protease Serine Protease |
|---|---|
| Autre Proteasome Inhibiteurs | MG132 Celastrol Epoxomicin (BU-4061T) ONX-0914 (PR-957) Oprozomib Delanzomib VR23 Marizomib (Salinosporamide A) PI-1840 KSQ-4279 (USP1-IN-1) |
| Lignées cellulaires | Type dessai | Concentration | Temps dincubation | Formulation | Description de lactivité | PMID |
|---|---|---|---|---|---|---|
| NCI-H1838 | Growth Inhibition Assay | IC50=4186.32 μM | SANGER | |||
| IMR-5 | Growth Inhibition Assay | IC50=3409.62 μM | SANGER | |||
| TE-441-T | Growth Inhibition Assay | IC50=2521.7 μM | SANGER | |||
| U-698-M | Growth Inhibition Assay | IC50=2262.15 μM | SANGER | |||
| COLO-824 | Growth Inhibition Assay | IC50=1261.78 μM | SANGER | |||
| P31-FUJ | Growth Inhibition Assay | IC50=1112.75 μM | SANGER | |||
| KY821 | Growth Inhibition Assay | IC50=1036.04 μM | SANGER | |||
| RPMI-8866 | Growth Inhibition Assay | IC50=1006.28 μM | SANGER | |||
| TC-YIK | Growth Inhibition Assay | IC50=781.01 nM | SANGER | |||
| MS-1 | Growth Inhibition Assay | IC50=759.42 nM | SANGER | |||
| DMS-153 | Growth Inhibition Assay | IC50=746.83 nM | SANGER | |||
| SUP-T1 | Growth Inhibition Assay | IC50=686.04 nM | SANGER | |||
| SCC-15 | Growth Inhibition Assay | IC50=667.47 nM | SANGER | |||
| MSTO-211H | Growth Inhibition Assay | IC50=574.26 nM | SANGER | |||
| J-RT3-T3-5 | Growth Inhibition Assay | IC50=532.57 nM | SANGER | |||
| NCI-H889 | Growth Inhibition Assay | IC50=461.92 nM | SANGER | |||
| CPC-N | Growth Inhibition Assay | IC50=403.77 nM | SANGER | |||
| COLO-668 | Growth Inhibition Assay | IC50=403.57 nM | SANGER | |||
| NCI-H226 | Growth Inhibition Assay | IC50=403.23 nM | SANGER | |||
| TUR | Growth Inhibition Assay | IC50=396.61 nM | SANGER | |||
| DEL | Growth Inhibition Assay | IC50=391.27 nM | SANGER | |||
| NCI-H1963 | Growth Inhibition Assay | IC50=386.19 nM | SANGER | |||
| CA46 | Growth Inhibition Assay | IC50=373.63 nM | SANGER | |||
| SNU-C1 | Growth Inhibition Assay | IC50=362.09 nM | SANGER | |||
| THP-1 | Growth Inhibition Assay | IC50=322.6 nM | SANGER | |||
| SCH | Growth Inhibition Assay | IC50=322.22 nM | SANGER | |||
| NCI-H1522 | Growth Inhibition Assay | IC50=307.05 nM | SANGER | |||
| LNCaP-Clone-FGC | Growth Inhibition Assay | IC50=295.26 nM | SANGER | |||
| NCI-H2171 | Growth Inhibition Assay | IC50=288.92 nM | SANGER | |||
| NCI-H187 | Growth Inhibition Assay | IC50=287.08 nM | SANGER | |||
| KASUMI-1 | Growth Inhibition Assay | IC50=283.05 nM | SANGER | |||
| SK-MEL-2 | Growth Inhibition Assay | IC50=281.9 nM | SANGER | |||
| EW-22 | Growth Inhibition Assay | IC50=263.75 nM | SANGER | |||
| NCI-H1299 | Growth Inhibition Assay | IC50=261.71 nM | SANGER | |||
| COR-L279 | Growth Inhibition Assay | IC50=252.17 nM | SANGER | |||
| NCI-H1155 | Growth Inhibition Assay | IC50=230.32 nM | SANGER | |||
| NCI-H1395 | Growth Inhibition Assay | IC50=210.13 nM | SANGER | |||
| KM-H2 | Growth Inhibition Assay | IC50=197.05 nM | SANGER | |||
| NCI-H209 | Growth Inhibition Assay | IC50=196.52 nM | SANGER | |||
| NCI-H510A | Growth Inhibition Assay | IC50=185.37 nM | SANGER | |||
| NCI-H1304 | Growth Inhibition Assay | IC50=169.21 nM | SANGER | |||
| SCLC-21H | Growth Inhibition Assay | IC50=159.41 nM | SANGER | |||
| NCI-H524 | Growth Inhibition Assay | IC50=159.1 nM | SANGER | |||
| MC116 | Growth Inhibition Assay | IC50=148.85 nM | SANGER | |||
| BV-173 | Growth Inhibition Assay | IC50=122.71 nM | SANGER | |||
| MHH-CALL-2 | Growth Inhibition Assay | IC50=115.7 nM | SANGER | |||
| NCI-H1650 | Growth Inhibition Assay | IC50=115.29 nM | SANGER | |||
| ST486 | Growth Inhibition Assay | IC50=114.06 nM | SANGER | |||
| GR-ST | Growth Inhibition Assay | IC50=113.34 nM | SANGER | |||
| SIG-M5 | Growth Inhibition Assay | IC50=105.06 nM | SANGER | |||
| NCI-H1770 | Growth Inhibition Assay | IC50=102.49 nM | SANGER | |||
| RH-1 | Growth Inhibition Assay | IC50=99.85 nM | SANGER | |||
| AM-38 | Growth Inhibition Assay | IC50=88.08 nM | SANGER | |||
| RL | Growth Inhibition Assay | IC50=86.09 nM | SANGER | |||
| CAL-148 | Growth Inhibition Assay | IC50=81.84 nM | SANGER | |||
| SK-N-FI | Growth Inhibition Assay | IC50=80.2 nM | SANGER | |||
| EW-11 | Growth Inhibition Assay | IC50=78.52 nM | SANGER | |||
| EW-13 | Growth Inhibition Assay | IC50=77.76 nM | SANGER | |||
| ALL-PO | Growth Inhibition Assay | IC50=77.66 nM | SANGER | |||
| KP-N-YS | Growth Inhibition Assay | IC50=76.74 nM | SANGER | |||
| KMS-12-PE | Growth Inhibition Assay | IC50=76.24 nM | SANGER | |||
| NCI-H128 | Growth Inhibition Assay | IC50=74.77 nM | SANGER | |||
| NCI-H322M | Growth Inhibition Assay | IC50=66.11 nM | SANGER | |||
| BT-474 | Growth Inhibition Assay | IC50=65 nM | SANGER | |||
| MRK-nu-1 | Growth Inhibition Assay | IC50=61.82 nM | SANGER | |||
| YT | Growth Inhibition Assay | IC50=61.8 nM | SANGER | |||
| LP-1 | Growth Inhibition Assay | IC50=61.28 nM | SANGER | |||
| P30-OHK | Growth Inhibition Assay | IC50=54.61 nM | SANGER | |||
| NCI-N87 | Growth Inhibition Assay | IC50=54.18 nM | SANGER | |||
| TALL-1 | Growth Inhibition Assay | IC50=53.91 nM | SANGER | |||
| MC-CAR | Growth Inhibition Assay | IC50=51.52 nM | SANGER | |||
| NCI-H720 | Growth Inhibition Assay | IC50=51.11 nM | SANGER | |||
| RS4-11 | Growth Inhibition Assay | IC50=50.88 nM | SANGER | |||
| DMS-79 | Growth Inhibition Assay | IC50=50.71 nM | SANGER | |||
| NCI-H716 | Growth Inhibition Assay | IC50=48.81 nM | SANGER | |||
| RPMI-6666 | Growth Inhibition Assay | IC50=45.89 nM | SANGER | |||
| L-428 | Growth Inhibition Assay | IC50=43.86 nM | SANGER | |||
| SKM-1 | Growth Inhibition Assay | IC50=42.63 nM | SANGER | |||
| NCI-H2227 | Growth Inhibition Assay | IC50=40.49 nM | SANGER | |||
| SHP-77 | Growth Inhibition Assay | IC50=38.03 nM | SANGER | |||
| D-283MED | Growth Inhibition Assay | IC50=37.79 nM | SANGER | |||
| MDA-MB-134-VI | Growth Inhibition Assay | IC50=35.87 nM | SANGER | |||
| C8166 | Growth Inhibition Assay | IC50=35.7 nM | SANGER | |||
| UACC-812 | Growth Inhibition Assay | IC50=35.44 nM | SANGER | |||
| ES3 | Growth Inhibition Assay | IC50=35.19 nM | SANGER | |||
| SK-MEL-1 | Growth Inhibition Assay | IC50=35.17 nM | SANGER | |||
| KARPAS-422 | Growth Inhibition Assay | IC50=35.04 nM | SANGER | |||
| NCI-H719 | Growth Inhibition Assay | IC50=34.31 nM | SANGER | |||
| NCI-H526 | Growth Inhibition Assay | IC50=32.54 nM | SANGER | |||
| EW-3 | Growth Inhibition Assay | IC50=30.59 nM | SANGER | |||
| OCI-AML2 | Growth Inhibition Assay | IC50=29.69 nM | SANGER | |||
| ECC4 | Growth Inhibition Assay | IC50=28.79 nM | SANGER | |||
| WSU-NHL | Growth Inhibition Assay | IC50=28.39 nM | SANGER | |||
| NH-12 | Growth Inhibition Assay | IC50=27.67 nM | SANGER | |||
| LU-165 | Growth Inhibition Assay | IC50=26.72 nM | SANGER | |||
| REH | Growth Inhibition Assay | IC50=26.41 nM | SANGER | |||
| LS-1034 | Growth Inhibition Assay | IC50=25.75 nM | SANGER | |||
| HDLM-2 | Growth Inhibition Assay | IC50=24.54 nM | SANGER | |||
| EC-GI-10 | Growth Inhibition Assay | IC50=24.23 nM | SANGER | |||
| IM-9 | Growth Inhibition Assay | IC50=23.54 nM | SANGER | |||
| DOHH-2 | Growth Inhibition Assay | IC50=23.45 nM | SANGER | |||
| SIMA | Growth Inhibition Assay | IC50=23.38 nM | SANGER | |||
| EW-12 | Growth Inhibition Assay | IC50=23.17 nM | SANGER | |||
| HCC2157 | Growth Inhibition Assay | IC50=23.13 nM | SANGER | |||
| NCI-H82 | Growth Inhibition Assay | IC50=23.02 nM | SANGER | |||
| IST-MES1 | Growth Inhibition Assay | IC50=22.77 nM | SANGER | |||
| NCI-H446 | Growth Inhibition Assay | IC50=21.18 nM | SANGER | |||
| SF539 | Growth Inhibition Assay | IC50=20.67 nM | SANGER | |||
| TE-6 | Growth Inhibition Assay | IC50=20.08 nM | SANGER | |||
| HCC2218 | Growth Inhibition Assay | IC50=19.5 nM | SANGER | |||
| DG-75 | Growth Inhibition Assay | IC50=18.61 nM | SANGER | |||
| NCCIT | Growth Inhibition Assay | IC50=18.36 nM | SANGER | |||
| EoL-1- | Growth Inhibition Assay | IC50=18.31 nM | SANGER | |||
| EB2 | Growth Inhibition Assay | IC50=18.08 nM | SANGER | |||
| NB14 | Growth Inhibition Assay | IC50=17.98 nM | SANGER | |||
| EW-18 | Growth Inhibition Assay | IC50=17.96 nM | SANGER | |||
| MFM-223 | Growth Inhibition Assay | IC50=17.91 nM | SANGER | |||
| COLO-800 | Growth Inhibition Assay | IC50=17.64 nM | SANGER | |||
| GOTO | Growth Inhibition Assay | IC50=17.06 nM | SANGER | |||
| NCI-H1436 | Growth Inhibition Assay | IC50=17.01 nM | SANGER | |||
| U-87-MG | Growth Inhibition Assay | IC50=16.76 nM | SANGER | |||
| TGW | Growth Inhibition Assay | IC50=16.48 nM | SANGER | |||
| JAR | Growth Inhibition Assay | IC50=16.13 nM | SANGER | |||
| NB7 | Growth Inhibition Assay | IC50=15.92 nM | SANGER | |||
| NCI-SNU-1 | Growth Inhibition Assay | IC50=13.19 nM | SANGER | |||
| JVM-3 | Growth Inhibition Assay | IC50=12.99 nM | SANGER | |||
| NCI-H1581 | Growth Inhibition Assay | IC50=12.28 nM | SANGER | |||
| NCI-H23 | Growth Inhibition Assay | IC50=12.12 nM | SANGER | |||
| HCC1599 | Growth Inhibition Assay | IC50=11.91 nM | SANGER | |||
| ES5 | Growth Inhibition Assay | IC50=10.38 nM | SANGER | |||
| NCI-H2081 | Growth Inhibition Assay | IC50=10.09 nM | SANGER | |||
| CTB-1 | Growth Inhibition Assay | IC50=9.67 nM | SANGER | |||
| DMS-114 | Growth Inhibition Assay | IC50=9.62 nM | SANGER | |||
| SK-NEP-1 | Growth Inhibition Assay | IC50=9.01 nM | SANGER | |||
| ATN-1 | Growth Inhibition Assay | IC50=8.89 nM | SANGER | |||
| MLMA | Growth Inhibition Assay | IC50=8.85 nM | SANGER | |||
| NB6 | Growth Inhibition Assay | IC50=8.48 nM | SANGER | |||
| MN-60 | Growth Inhibition Assay | IC50=8.14 nM | SANGER | |||
| KG-1 | Growth Inhibition Assay | IC50=7.94 nM | SANGER | |||
| L-363 | Growth Inhibition Assay | IC50=7.7 nM | SANGER | |||
| NCI-SNU-16 | Growth Inhibition Assay | IC50=7.65 nM | SANGER | |||
| NCI-H1694 | Growth Inhibition Assay | IC50=7.58 nM | SANGER | |||
| LU-134-A | Growth Inhibition Assay | IC50=7.39 nM | SANGER | |||
| JVM-2 | Growth Inhibition Assay | IC50=7.28 nM | SANGER | |||
| SU-DHL-1 | Growth Inhibition Assay | IC50=7.24 nM | SANGER | |||
| NCI-H345 | Growth Inhibition Assay | IC50=7.2 nM | SANGER | |||
| NB1 | Growth Inhibition Assay | IC50=6.88 nM | SANGER | |||
| NCI-H2196 | Growth Inhibition Assay | IC50=6.8 nM | SANGER | |||
| GDM-1 | Growth Inhibition Assay | IC50=6.77 nM | SANGER | |||
| BC-3 | Growth Inhibition Assay | IC50=6.61 nM | SANGER | |||
| D-502MG | Growth Inhibition Assay | IC50=6.37 nM | SANGER | |||
| LU-65 | Growth Inhibition Assay | IC50=5.84 nM | SANGER | |||
| NCI-H1417 | Growth Inhibition Assay | IC50=5.51 nM | SANGER | |||
| EW-1 | Growth Inhibition Assay | IC50=5.31 nM | SANGER | |||
| SW962 | Growth Inhibition Assay | IC50=5.21 nM | SANGER | |||
| NCI-SNU-5 | Growth Inhibition Assay | IC50=5.17 nM | SANGER | |||
| LU-139 | Growth Inhibition Assay | IC50=5.13 nM | SANGER | |||
| CHP-126 | Growth Inhibition Assay | IC50=5.06 nM | SANGER | |||
| SBC-1 | Growth Inhibition Assay | IC50=5.01 nM | SANGER | |||
| JiyoyeP-2003 | Growth Inhibition Assay | IC50=5 nM | SANGER | |||
| MHH-NB-11 | Growth Inhibition Assay | IC50=4.91 nM | SANGER | |||
| MHH-PREB-1 | Growth Inhibition Assay | IC50=4.86 nM | SANGER | |||
| IST-SL1 | Growth Inhibition Assay | IC50=4.68 nM | SANGER | |||
| HL-60 | Growth Inhibition Assay | IC50=4.67 nM | SANGER | |||
| NALM-6 | Growth Inhibition Assay | IC50=4.49 nM | SANGER | |||
| Raji | Growth Inhibition Assay | IC50=4.46 nM | SANGER | |||
| NOMO-1 | Growth Inhibition Assay | IC50=4.33 nM | SANGER | |||
| TE-12 | Growth Inhibition Assay | IC50=4.25 nM | SANGER | |||
| LB647-SCLC | Growth Inhibition Assay | IC50=4.22 nM | SANGER | |||
| OMC-1 | Growth Inhibition Assay | IC50=4.18 nM | SANGER | |||
| NCI-H1648 | Growth Inhibition Assay | IC50=4.13 nM | SANGER | |||
| K-562 | Growth Inhibition Assay | IC50=4.12 nM | SANGER | |||
| NCI-H2141 | Growth Inhibition Assay | IC50=4.05 nM | SANGER | |||
| HD-MY-Z | Growth Inhibition Assay | IC50=3.93 nM | SANGER | |||
| RCC10RGB | Growth Inhibition Assay | IC50=3.93 nM | SANGER | |||
| COLO-320-HSR | Growth Inhibition Assay | IC50=3.92 nM | SANGER | |||
| RL95-2 | Growth Inhibition Assay | IC50=3.79 nM | SANGER | |||
| LC-1F | Growth Inhibition Assay | IC50=3.74 nM | SANGER | |||
| NMC-G1 | Growth Inhibition Assay | IC50=3.68 nM | SANGER | |||
| COLO-684 | Growth Inhibition Assay | IC50=3.66 nM | SANGER | |||
| DJM-1 | Growth Inhibition Assay | IC50=3.63 nM | SANGER | |||
| EVSA-T | Growth Inhibition Assay | IC50=3.6 nM | SANGER | |||
| no-11 | Growth Inhibition Assay | IC50=3.55 nM | SANGER | |||
| MZ1-PC | Growth Inhibition Assay | IC50=3.54 nM | SANGER | |||
| HCC1187 | Growth Inhibition Assay | IC50=3.54 nM | SANGER | |||
| KARPAS-45 | Growth Inhibition Assay | IC50=3.54 nM | SANGER | |||
| RPMI-8402 | Growth Inhibition Assay | IC50=3.5 nM | SANGER | |||
| LOXIMVI | Growth Inhibition Assay | IC50=3.5 nM | SANGER | |||
| MEG-01 | Growth Inhibition Assay | IC50=3.49 nM | SANGER | |||
| LAMA-84 | Growth Inhibition Assay | IC50=3.49 nM | SANGER | |||
| COR-L88 | Growth Inhibition Assay | IC50=3.47 nM | SANGER | |||
| TE-15 | Growth Inhibition Assay | IC50=3.43 nM | SANGER | |||
| DB | Growth Inhibition Assay | IC50=3.41 nM | SANGER | |||
| LB996-RCC | Growth Inhibition Assay | IC50=3.4 nM | SANGER | |||
| NEC8 | Growth Inhibition Assay | IC50=3.35 nM | SANGER | |||
| SK-N-DZ | Growth Inhibition Assay | IC50=3.26 nM | SANGER | |||
| CW-2 | Growth Inhibition Assay | IC50=3.21 nM | SANGER | |||
| SK-PN-DW | Growth Inhibition Assay | IC50=3.14 nM | SANGER | |||
| CGTH-W-1 | Growth Inhibition Assay | IC50=3.1 nM | SANGER | |||
| MONO-MAC-6 | Growth Inhibition Assay | IC50=3.1 nM | SANGER | |||
| KARPAS-299 | Growth Inhibition Assay | IC50=3.06 nM | SANGER | |||
| HT | Growth Inhibition Assay | IC50=3.02 nM | SANGER | |||
| SW954 | Growth Inhibition Assay | IC50=2.9 nM | SANGER | |||
| MOLT-16 | Growth Inhibition Assay | IC50=2.89 nM | SANGER | |||
| C2BBe1 | Growth Inhibition Assay | IC50=2.89 nM | SANGER | |||
| ETK-1 | Growth Inhibition Assay | IC50=2.84 nM | SANGER | |||
| CTV-1 | Growth Inhibition Assay | IC50=2.8 nM | SANGER | |||
| EW-16 | Growth Inhibition Assay | IC50=2.75 nM | SANGER | |||
| Mo-T | Growth Inhibition Assay | IC50=2.74 nM | SANGER | |||
| EB-3 | Growth Inhibition Assay | IC50=2.66 nM | SANGER | |||
| LB1047-RCC | Growth Inhibition Assay | IC50=2.57 nM | SANGER | |||
| KNS-81-FD | Growth Inhibition Assay | IC50=2.48 nM | SANGER | |||
| NB69 | Growth Inhibition Assay | IC50=2.46 nM | SANGER | |||
| NCI-H64 | Growth Inhibition Assay | IC50=2.44 nM | SANGER | |||
| KU812 | Growth Inhibition Assay | IC50=2.42 nM | SANGER | |||
| NCI-H748 | Growth Inhibition Assay | IC50=2.39 nM | SANGER | |||
| ARH-77 | Growth Inhibition Assay | IC50=2.38 nM | SANGER | |||
| SCC-3 | Growth Inhibition Assay | IC50=2.37 nM | SANGER | |||
| RPMI-8226 | Growth Inhibition Assay | IC50=2.35 nM | SANGER | |||
| NB10 | Growth Inhibition Assay | IC50=2.32 nM | SANGER | |||
| BC-1 | Growth Inhibition Assay | IC50=2.31 nM | SANGER | |||
| NB5 | Growth Inhibition Assay | IC50=2.27 nM | SANGER | |||
| KMOE-2 | Growth Inhibition Assay | IC50=2.23 nM | SANGER | |||
| SJSA-1 | Growth Inhibition Assay | IC50=2.21 nM | SANGER | |||
| ES4 | Growth Inhibition Assay | IC50=2.16 nM | SANGER | |||
| KGN | Growth Inhibition Assay | IC50=2.15 nM | SANGER | |||
| EKVX | Growth Inhibition Assay | IC50=2.14 nM | SANGER | |||
| MOLT-4 | Growth Inhibition Assay | IC50=2.13 nM | SANGER | |||
| KE-37 | Growth Inhibition Assay | IC50=2.13 nM | SANGER | |||
| HH | Growth Inhibition Assay | IC50=2.13 nM | SANGER | |||
| GT3TKB | Growth Inhibition Assay | IC50=2.12 nM | SANGER | |||
| BL-70 | Growth Inhibition Assay | IC50=2.12 nM | SANGER | |||
| NOS-1 | Growth Inhibition Assay | IC50=2.11 nM | SANGER | |||
| EW-24 | Growth Inhibition Assay | IC50=2.08 nM | SANGER | |||
| LAN-6 | Growth Inhibition Assay | IC50=2.05 nM | SANGER | |||
| NB17 | Growth Inhibition Assay | IC50=2.04 nM | SANGER | |||
| LS-123 | Growth Inhibition Assay | IC50=2.02 nM | SANGER | |||
| NB13 | Growth Inhibition Assay | IC50=2 nM | SANGER | |||
| NKM-1 | Growth Inhibition Assay | IC50=2 nM | SANGER | |||
| 697 | Growth Inhibition Assay | IC50=1.99 nM | SANGER | |||
| BE-13 | Growth Inhibition Assay | IC50=1.93 nM | SANGER | |||
| MPP-89 | Growth Inhibition Assay | IC50=1.89 nM | SANGER | |||
| Becker | Growth Inhibition Assay | IC50=1.83 nM | SANGER | |||
| MV-4-11 | Growth Inhibition Assay | IC50=1.82 nM | SANGER | |||
| GB-1 | Growth Inhibition Assay | IC50=1.81 nM | SANGER | |||
| NCI-H1092 | Growth Inhibition Assay | IC50=1.8 nM | SANGER | |||
| NCI-H2126 | Growth Inhibition Assay | IC50=1.8 nM | SANGER | |||
| LC4-1 | Growth Inhibition Assay | IC50=1.79 nM | SANGER | |||
| U-266 | Growth Inhibition Assay | IC50=1.76 nM | SANGER | |||
| KURAMOCHI | Growth Inhibition Assay | IC50=1.72 nM | SANGER | |||
| TGBC1TKB | Growth Inhibition Assay | IC50=1.71 nM | SANGER | |||
| EHEB | Growth Inhibition Assay | IC50=1.67 nM | SANGER | |||
| GCIY | Growth Inhibition Assay | IC50=1.62 nM | SANGER | |||
| HEL | Growth Inhibition Assay | IC50=1.61 nM | SANGER | |||
| NB12 | Growth Inhibition Assay | IC50=1.56 nM | SANGER | |||
| NCI-H69 | Growth Inhibition Assay | IC50=1.54 nM | SANGER | |||
| LS-411N | Growth Inhibition Assay | IC50=1.53 nM | SANGER | |||
| PF-382 | Growth Inhibition Assay | IC50=1.47 nM | SANGER | |||
| CAS-1 | Growth Inhibition Assay | IC50=1.37 nM | SANGER | |||
| L-540 | Growth Inhibition Assay | IC50=1.37 nM | SANGER | |||
| ECC12 | Growth Inhibition Assay | IC50=1.37 nM | SANGER | |||
| DU-4475 | Growth Inhibition Assay | IC50=1.36 nM | SANGER | |||
| OPM-2 | Growth Inhibition Assay | IC50=1.33 nM | SANGER | |||
| IST-SL2 | Growth Inhibition Assay | IC50=1.31 nM | SANGER | |||
| Calu-6 | Growth Inhibition Assay | IC50=1.29 nM | SANGER | |||
| CMK | Growth Inhibition Assay | IC50=1.29 nM | SANGER | |||
| A3-KAW | Growth Inhibition Assay | IC50=1.28 nM | SANGER | |||
| K5 | Growth Inhibition Assay | IC50=1.28 nM | SANGER | |||
| KM12 | Growth Inhibition Assay | IC50=1.27 nM | SANGER | |||
| SR | Growth Inhibition Assay | IC50=1.25 nM | SANGER | |||
| BL-41 | Growth Inhibition Assay | IC50=1.25 nM | SANGER | |||
| Daudi | Growth Inhibition Assay | IC50=1.22 nM | SANGER | |||
| NCI-H1882 | Growth Inhibition Assay | IC50=1.2 nM | SANGER | |||
| TE-8 | Growth Inhibition Assay | IC50=1.19 nM | SANGER | |||
| HAL-01 | Growth Inhibition Assay | IC50=1.18 nM | SANGER | |||
| EM-2 | Growth Inhibition Assay | IC50=1.16 nM | SANGER | |||
| CCRF-CEM | Growth Inhibition Assay | IC50=1.13 nM | SANGER | |||
| D-392MG | Growth Inhibition Assay | IC50=1.1 nM | SANGER | |||
| MZ7-mel | Growth Inhibition Assay | IC50=1.09 nM | SANGER | |||
| VA-ES-BJ | Growth Inhibition Assay | IC50=1.09 nM | SANGER | |||
| SK-MM-2 | Growth Inhibition Assay | IC50=1.09 nM | SANGER | |||
| LC-2-ad | Growth Inhibition Assay | IC50=1.08 nM | SANGER | |||
| RKO | Growth Inhibition Assay | IC50=1.06 nM | SANGER | |||
| TE-10 | Growth Inhibition Assay | IC50=1.03 nM | SANGER | |||
| TE-1 | Growth Inhibition Assay | IC50=1.03 nM | SANGER | |||
| PSN1 | Growth Inhibition Assay | IC50=1.01 nM | SANGER | |||
| SW872 | Growth Inhibition Assay | IC50=0.996 nM | SANGER | |||
| HC-1 | Growth Inhibition Assay | IC50=0.975 nM | SANGER | |||
| KALS-1 | Growth Inhibition Assay | IC50=0.925 nM | SANGER | |||
| SF268 | Growth Inhibition Assay | IC50=0.923 nM | SANGER | |||
| IST-MEL1 | Growth Inhibition Assay | IC50=0.917 nM | SANGER | |||
| RXF393 | Growth Inhibition Assay | IC50=0.914 nM | SANGER | |||
| SNB75 | Growth Inhibition Assay | IC50=0.912 nM | SANGER | |||
| NCI-H1355 | Growth Inhibition Assay | IC50=0.895 nM | SANGER | |||
| TE-5 | Growth Inhibition Assay | IC50=0.865 nM | SANGER | |||
| QIMR-WIL | Growth Inhibition Assay | IC50=0.889 nM | SANGER | |||
| SK-LMS-1 | Growth Inhibition Assay | IC50=0.854 nM | SANGER | |||
| SW684 | Growth Inhibition Assay | IC50=0.821 nM | SANGER | |||
| ML-2 | Growth Inhibition Assay | IC50=0.821 nM | SANGER | |||
| D-263MG | Growth Inhibition Assay | IC50=0.807 nM | SANGER | |||
| LB2241-RCC | Growth Inhibition Assay | IC50=0.804 nM | SANGER | |||
| GI-1 | Growth Inhibition Assay | IC50=0.764 nM | SANGER | |||
| ES7 | Growth Inhibition Assay | IC50=0.766 nM | SANGER | |||
| LS-513 | Growth Inhibition Assay | IC50=0.739 nM | SANGER | |||
| KINGS-1 | Growth Inhibition Assay | IC50=0.722 nM | SANGER | |||
| UACC-257 | Growth Inhibition Assay | IC50=0.71 nM | SANGER | |||
| LB373-MEL-D | Growth Inhibition Assay | IC50=0.7 nM | SANGER | |||
| SF126 | Growth Inhibition Assay | IC50=0.701 nM | SANGER | |||
| Ramos-2G6-4C10 | Growth Inhibition Assay | IC50=0.693 nM | SANGER | |||
| TK10 | Growth Inhibition Assay | IC50=0.679 nM | SANGER | |||
| D-336MG | Growth Inhibition Assay | IC50=0.657 nM | SANGER | |||
| BB49-HNC | Growth Inhibition Assay | IC50=0.652 nM | SANGER | |||
| HOP-62 | Growth Inhibition Assay | IC50=0.647 nM | SANGER | |||
| LB831-BLC | Growth Inhibition Assay | IC50=0.641 nM | SANGER | |||
| GI-ME-N | Growth Inhibition Assay | IC50=0.634 nM | SANGER | |||
| A4-Fuk | Growth Inhibition Assay | IC50=0.623 nM | SANGER | |||
| HT-144 | Growth Inhibition Assay | IC50=0.576 nM | SANGER | |||
| COLO-829 | Growth Inhibition Assay | IC50=0.614 nM | SANGER | |||
| NCI-H747 | Growth Inhibition Assay | IC50=0.539 nM | SANGER | |||
| CESS | Growth Inhibition Assay | IC50=0.538 nM | SANGER | |||
| HUTU-80 | Growth Inhibition Assay | IC50=0.533 nM | SANGER | |||
| DSH1 | Growth Inhibition Assay | IC50=0.48 nM | SANGER | |||
| LB771-HNC | Growth Inhibition Assay | IC50=0.474 nM | SANGER | |||
| CP66-MEL | Growth Inhibition Assay | IC50=0.473 nM | SANGER | |||
| OCUB-M | Growth Inhibition Assay | IC50=0.447 nM | SANGER | |||
| MFH-ino | Growth Inhibition Assay | IC50=0.443 nM | SANGER | |||
| OS-RC-2 | Growth Inhibition Assay | IC50=0.44 nM | SANGER | |||
| HCE-T | Growth Inhibition Assay | IC50=0.439 nM | SANGER | |||
| ES1 | Growth Inhibition Assay | IC50=0.43 nM | SANGER | |||
| LB2518-MEL | Growth Inhibition Assay | IC50=0.425 nM | SANGER | |||
| ACN | Growth Inhibition Assay | IC50=0.417 nM | SANGER | |||
| D-247MG | Growth Inhibition Assay | IC50=0.413 nM | SANGER | |||
| HCC2998 | Growth Inhibition Assay | IC50=0.412 nM | SANGER | |||
| MZ2-MEL | Growth Inhibition Assay | IC50=0.407 nM | SANGER | |||
| ES8 | Growth Inhibition Assay | IC50=0.4 nM | SANGER | |||
| A388 | Growth Inhibition Assay | IC50=0.356 nM | SANGER | |||
| KS-1 | Growth Inhibition Assay | IC50=0.34 nM | SANGER | |||
| BB30-HNC | Growth Inhibition Assay | IC50=0.335 nM | SANGER | |||
| ONS-76 | Growth Inhibition Assay | IC50=0.33 nM | SANGER | |||
| D-542MG | Growth Inhibition Assay | IC50=0.329 nM | SANGER | |||
| BB65-RCC | Growth Inhibition Assay | IC50=0.304 nM | SANGER | |||
| LOUCY | Growth Inhibition Assay | IC50=0.293 nM | SANGER | |||
| OVCAR-4 | Growth Inhibition Assay | IC50=0.289 nM | SANGER | |||
| LXF-289 | Growth Inhibition Assay | IC50=0.269 nM | SANGER | |||
| KNS-42 | Growth Inhibition Assay | IC50=0.258 nM | SANGER | |||
| 8-MG-BA | Growth Inhibition Assay | IC50=0.25 nM | SANGER | |||
| NTERA-S-cl-D1 | Growth Inhibition Assay | IC50=0.243 nM | SANGER | |||
| A101D | Growth Inhibition Assay | IC50=0.225 nM | SANGER | |||
| MMAC-SF | Growth Inhibition Assay | IC50=0.216 nM | SANGER | |||
| no-10 | Growth Inhibition Assay | IC50=0.21 nM | SANGER | |||
| A253 | Growth Inhibition Assay | IC50=0.208 nM | SANGER | |||
| TE-9 | Growth Inhibition Assay | IC50=0.182 nM | SANGER | |||
| SH-4 | Growth Inhibition Assay | IC50=0.173 nM | SANGER | |||
| SK-UT-1 | Growth Inhibition Assay | IC50=0.163 nM | SANGER | |||
| ES6 | Growth Inhibition Assay | IC50=0.0021 nM | SANGER | |||
| human PBMC | Function Assay | 100 nM | 24 h | Induces IL-8 release | 25791477 | |
| U937 | Function Assay | 100 nM | 6 h | Induces IL-8 expression in LPS-stimulated U937 macrophages | 25791477 | |
| HH | Migration Assay | 100 nM | 24 h | DMSO | Reduces cell migration by 80–91% | 25681335 |
| Hut-78 | Migration Assay | 100 nM | 24 h | DMSO | Reduces cell migration by 80–90% | 25681335 |
| HH | Function Assay | 100 nM | 24 h | DMSO | downregulates TGF-β1 and IL-12 expression | 25681335 |
| H9 | Function Assay | 100 nM | 24 h | DMSO | Downregulates TGF-β1 and IL-11 expression | 25681335 |
| Hut-78 | Function Assay | 100 nM | 24 h | DMSO | Downregulates TGF-β1 and IL-10 expression | 25681335 |
| H1299 | Apoptosis Assay | 80 nM | 24 h | DMSO | Sensitizes NSCLC cells to MSC-derived iC9-induced apoptosis | 25323693 |
| BLM | Autophagy Assay | 10 nM | 12 h | Induces formation of autophagosomes | 23079083 | |
| A375 | Autophagy Assay | 10 nM | 12 h | Induces formation of autophagosomes | 23079083 | |
| BLM | Apoptosis Assay | 10 nM | 24 h | Induces cell apoptosis | 23079083 | |
| A375 | Apoptosis Assay | 10 nM | 24 h | Induces cell apoptosis | 23079083 | |
| RAW 264.7 | Growth Inhibition Assay | 100 nM | 48 h | Reduces cell viability | 22427154 | |
| SNK-6 | Antiviral Assay | 1 μM | 24 h | Induces lytic infection of EBV | 21170988 | |
| KAI-3 | Antiviral Assay | 1 μM | 24 h | Induces lytic infection of EBV | 21170988 | |
| SNT-16 | Antiviral Assay | 1 μM | 24 h | Induces lytic infection of EBV | 21170988 | |
| SNT-13 | Antiviral Assay | 1 μM | 24 h | Induces lytic infection of EBV | 21170988 | |
| KHYG-1 | Apoptosis Assay | 1 μM | 6 h | Induces cell apoptosis | 21170988 | |
| KAI-3 | Apoptosis Assay | 1 μM | 6 h | Induces cell apoptosis | 21170988 | |
| Jurkat | Apoptosis Assay | 1 μM | 6 h | Induces cell apoptosis | 21170988 | |
| SNT-16 | Apoptosis Assay | 1 μM | 6 h | Induces cell apoptosis | 21170988 | |
| KHYG-1 | Growth Inhibition Assay | 1 μM | 24 h | Reduces cell viability | 21170988 | |
| SNK-6 | Growth Inhibition Assay | 1 μM | 24 h | Reduces cell viability | 21170988 | |
| KAI-3 | Growth Inhibition Assay | 1 μM | 24 h | Reduces cell viability | 21170988 | |
| Jurkat | Growth Inhibition Assay | 1 μM | 24 h | Reduces cell viability | 21170988 | |
| SNT-16 | Growth Inhibition Assay | 1 μM | 24 h | Reduces cell viability | 21170988 | |
| SNT-13 | Growth Inhibition Assay | 1 μM | 24 h | Reduces cell viability | 21170988 | |
| BJAB | Growth Inhibition Assay | 1 μM | 24 h | Reduces cell viability | 21170988 | |
| LCL-2 | Growth Inhibition Assay | 1 μM | 24 h | Reduces cell viability | 21170988 | |
| LCL-1 | Growth Inhibition Assay | 1 μM | 24 h | Reduces cell viability | 21170988 | |
| Raji | Growth Inhibition Assay | 1 μM | 24 h | Reduces cell viability | 21170988 | |
| BaF/3-p210 | Function Assay | 6 nM | 24 h | Reduces the phosphorylation and the activity of Rb | 20305692 | |
| BaF/3-p210 | Function Assay | 6 nM | 48 h | Induces a slight G1 cell-cycle arrest | 20305692 | |
| BaF/3 | Function Assay | 6 nM | 48 h | Induces a great G1 cell-cycle arrest | 20305692 | |
| TCC-S | Growth Inhibition Assay | 100 nM | 48 h | IC50=2.8 nM | 20305692 | |
| BaF/3-p210 | Growth Inhibition Assay | 100 nM | 48 h | IC50=4.7 nM | 20305692 | |
| BaF/3 | Growth Inhibition Assay | 100 nM | 48 h | IC50=6.2 nM | 20305692 | |
| RPMI 8226 | Function Assay | 20 nM | 8 h | Induces DNA synthesis | 19436050 | |
| OPM2 | Function Assay | 20 nM | 8 h | Significantly enhances NF-κB activity | 19436050 | |
| INA6 | Function Assay | 20 nM | 8 h | Significantly enhances NF-κB activity | 19436050 | |
| OPM1 | Function Assay | 20 nM | 8 h | Significantly enhances NF-κB activity | 19436050 | |
| U266 | Function Assay | 20 nM | 8 h | Significantly enhances NF-κB activity | 19436050 | |
| MM.1S | Function Assay | 20 nM | 8 h | Significantly enhances NF-κB activity | 19436050 | |
| RPMI 8226 | Function Assay | 20 nM | 8 h | Significantly enhances NF-κB activity | 19436050 | |
| CHLA-255 | Function Assay | 10 nM | 24 h | Modestly reduces cells in the G0/G1 phase | 17689684 | |
| NB-1691 | Function Assay | 10 nM | 24 h | Significantly reduces cells in the G0/G1 phase | 17689684 | |
| SK-N-AS | Growth Inhibition Assay | 1 μM | 72 h | Inhibits cell proliferation to 10% | 17689684 | |
| CHLA-255 | Growth Inhibition Assay | 1 μM | 72 h | Inhibits cell proliferation to 2% | 17689684 | |
| NB-1691 | Growth Inhibition Assay | 1 μM | 72 h | Inhibits cell proliferation to 5% | 17689684 | |
| HKe-3 | Apoptosis Assay | 50 nM | 48 h | DMSO | Induces cell apoptosis | 16778179 |
| HCT116 | Apoptosis Assay | 50 nM | 48 h | DMSO | Induces cell apoptosis | 16778179 |
| T29Kt1 | Apoptosis Assay | 50 nM | 48 h | DMSO | Induces cell apoptosis | 16778179 |
| T29 | Apoptosis Assay | 50 nM | 48 h | DMSO | Induces cell apoptosis | 16778179 |
| LNCap-Pro5 | Function Assay | 1 μM | 4 h | DMSO | Stabilizes p53 | 14612532 |
| H460 | Function Assay | 100 nM | 24 h | DMSO | Induces G2-M-phase arrest and tubulin assembly-disassembly | 12631620 |
| H322 | Growth Inhibition Assay | 10 μM | 72 h | DMSO | IC50=620 nM | 12631620 |
| H358 | Growth Inhibition Assay | 10 μM | 72 h | DMSO | IC50=70 nM | 12631620 |
| H460 | Growth Inhibition Assay | 10 μM | 72 h | DMSO | IC50=100 nM | 12631620 |
| RPMI8226/LR5 | Growth Inhibition Assay | 500 ng/ml | 48 h | DMSO | Inhibits cell growth | 12631619 |
| U266/dox4 | Growth Inhibition Assay | 500 ng/ml | 48 h | DMSO | Inhibits cell growth | 12631619 |
| U266/LR7 | Growth Inhibition Assay | 500 ng/ml | 48 h | DMSO | Inhibits cell growth | 12631619 |
| WAD-1 | Growth Inhibition Assay | 500 ng/ml | 48 h | DMSO | Inhibits cell growth | 12631619 |
| ARH77 | Growth Inhibition Assay | 500 ng/ml | 48 h | DMSO | Inhibits cell growth | 12631619 |
| U266 | Growth Inhibition Assay | 500 ng/ml | 48 h | DMSO | Inhibits cell growth | 12631619 |
| H460 | Function Assay | 10 μM | 24 h | DMSO | Induces Bcl-2 phosphorylation and cleavage correlated with G2-M phase arrest | 12492117 |
| UM-SCC-11B | Growth Inhibition Assay | 100 nM | 72 h | DMSO | Inhibits cell viability | 11350913 |
| UM-SCC-9 | Growth Inhibition Assay | 100 nM | 72 h | DMSO | Inhibits cell viability | 11350913 |
| B7E3 | Growth Inhibition Assay | 100 nM | 72 h | DMSO | Inhibits cell viability | 11350913 |
| B4B8 | Growth Inhibition Assay | 100 nM | 72 h | DMSO | Inhibits cell viability | 11350913 |
| PAM-LY2 | Growth Inhibition Assay | 100 nM | 72 h | DMSO | Inhibits cell viability | 11350913 |
| PAM 212 | Growth Inhibition Assay | 100 nM | 72 h | DMSO | Inhibits cell viability | 11350913 |
| PAM-LY2 | Function Assay | 100 nM | 12 h | DMSO | Inhibits NF-κB activation | 11350913 |
| Hs Sultan | Growth Inhibition Assay | 100 nM | 48 h | DMSO | IC50=20 nM | 11306489 |
| IM-9 | Growth Inhibition Assay | 100 nM | 48 h | DMSO | IC50=6 nM | 11306489 |
| U266 | Growth Inhibition Assay | 100 nM | 48 h | DMSO | IC50=3 nM | 11306489 |
| LR5 | Growth Inhibition Assay | 100 nM | 48 h | DMSO | IC50=20 nM | 11306489 |
| MR20 | Growth Inhibition Assay | 100 nM | 48 h | DMSO | IC50=20 nM | 11306489 |
| Dox40 | Growth Inhibition Assay | 100 nM | 48 h | DMSO | IC50=40 nM | 11306489 |
| RPMI8226 | Growth Inhibition Assay | 100 nM | 48 h | DMSO | IC50=30 nM | 11306489 |
| OVCA 429 | Function Assay | 300 nM | 48 h | DMSO | Disrupts intact multicellular tumor spheroids | 10999766 |
| MCF-7 | Cytotoxic Assay | 50 μM | 48 h | DMSO | Kills cells by more than 99% | 10499643 |
| FSCLL | Cytotoxicity assay | 24 hrs | CC50 = 0.004 μM | 21634429 | ||
| HEK293 | Cytotoxicity assay | 24 hrs | CC50 = 0.347 μM | 21634429 | ||
| Glioma (HF2303) | Cytotoxicity assay | 72 hrs | EC50 = 0.0007 μM | 26288699 | ||
| Glioma (HF2476) | Cytotoxicity assay | 72 hrs | EC50 = 0.0007 μM | 26288699 | ||
| Glioma (HF2876) | Cytotoxicity assay | 72 hrs | EC50 = 0.0007 μM | 26288699 | ||
| Glioma (HF2885) | Cytotoxicity assay | 72 hrs | EC50 = 0.0007 μM | 26288699 | ||
| Glioma (HF3013) | Cytotoxicity assay | 72 hrs | EC50 = 0.0007 μM | 26288699 | ||
| Glioma (HF2381) | Cytotoxicity assay | 72 hrs | EC50 = 0.0007 μM | 26288699 | ||
| Glioma (HF2790) | Cytotoxicity assay | 72 hrs | EC50 = 0.0007 μM | 26288699 | ||
| HepG2 | Cytotoxicity assay | 48 hrs | EC50 = 0.01 μM | 29800827 | ||
| Molt4 | Function assay | EC50 = 0.021 μM | 18247547 | |||
| Molt4 | Function assay | EC50 = 0.021 μM | 22503349 | |||
| HL60 | Function assay | 10 mins | ED50 = 0.0025 μM | 19422206 | ||
| HL60 | Function assay | 10 mins | ED50 = 0.0025 μM | 21973101 | ||
| RPMI8226 | Growth inhibition assay | GI50 = 0.00023 μM | 24946214 | |||
| CCRF-CEM | Growth inhibition assay | GI50 = 0.00035 μM | 24946214 | |||
| MDA-MB-435 | Growth inhibition assay | GI50 = 0.00044 μM | 24946214 | |||
| MALME-3M | Growth inhibition assay | GI50 = 0.00045 μM | 24946214 | |||
| NCI-H226 | Growth inhibition assay | GI50 = 0.00046 μM | 24946214 | |||
| SK-MEL-28 | Growth inhibition assay | GI50 = 0.00046 μM | 24946214 | |||
| A498 | Growth inhibition assay | GI50 = 0.00048 μM | 24946214 | |||
| MOLT4 | Growth inhibition assay | GI50 = 0.00051 μM | 24946214 | |||
| OVCAR3 | Growth inhibition assay | GI50 = 0.00054 μM | 24946214 | |||
| SW620 | Growth inhibition assay | GI50 = 0.00055 μM | 24946214 | |||
| MCF7 | Growth inhibition assay | GI50 = 0.00055 μM | 24946214 | |||
| BT549 | Growth inhibition assay | GI50 = 0.00055 μM | 24946214 | |||
| UACC257 | Growth inhibition assay | GI50 = 0.00059 μM | 24946214 | |||
| SF539 | Growth inhibition assay | GI50 = 0.00059 μM | 24946214 | |||
| HCC2998 | Growth inhibition assay | GI50 = 0.0006 μM | 24946214 | |||
| HCT116 | Growth inhibition assay | GI50 = 0.0006 μM | 24946214 | |||
| T47D | Growth inhibition assay | GI50 = 0.0006 μM | 24946214 | |||
| CAKI-1 | Growth inhibition assay | GI50 = 0.00066 μM | 24946214 | |||
| SK-MEL-5 | Growth inhibition assay | GI50 = 0.00068 μM | 24946214 | |||
| RXF393 | Growth inhibition assay | GI50 = 0.00071 μM | 24946214 | |||
| LOXIMVI | Growth inhibition assay | GI50 = 0.00078 μM | 24946214 | |||
| ACHN | Growth inhibition assay | GI50 = 0.00079 μM | 24946214 | |||
| SR | Growth inhibition assay | GI50 = 0.00085 μM | 24946214 | |||
| UACC62 | Growth inhibition assay | GI50 = 0.00091 μM | 24946214 | |||
| M14 | Growth inhibition assay | GI50 = 0.00093 μM | 24946214 | |||
| HT-29 | Growth inhibition assay | GI50 = 0.00095 μM | 24946214 | |||
| HOP92 | Growth inhibition assay | GI50 = 0.001 μM | 24946214 | |||
| NCI-H23 | Growth inhibition assay | GI50 = 0.001 μM | 24946214 | |||
| TK10 | Growth inhibition assay | GI50 = 0.001 μM | 24946214 | |||
| CEM | Antiproliferative assay | 72 hrs | GI50 = 0.001 μM | 28441582 | ||
| U266 | Antiproliferative assay | 72 hrs | GI50 = 0.001 μM | 28441582 | ||
| Hs 578T | Growth inhibition assay | GI50 = 0.00102 μM | 24946214 | |||
| UO31 | Growth inhibition assay | GI50 = 0.00105 μM | 24946214 | |||
| SK-MEL-2 | Growth inhibition assay | GI50 = 0.00107 μM | 24946214 | |||
| SN12C | Growth inhibition assay | GI50 = 0.0011 μM | 24946214 | |||
| K562 | Growth inhibition assay | GI50 = 0.00117 μM | 24946214 | |||
| SF268 | Growth inhibition assay | GI50 = 0.00117 μM | 24946214 | |||
| COLO205 | Growth inhibition assay | GI50 = 0.00123 μM | 24946214 | |||
| MDA-MB-231 | Growth inhibition assay | GI50 = 0.00126 μM | 24946214 | |||
| NCI-H522 | Growth inhibition assay | GI50 = 0.00144 μM | 24946214 | |||
| 786-0 | Growth inhibition assay | GI50 = 0.00144 μM | 24946214 | |||
| MDA-MB-468 | Growth inhibition assay | GI50 = 0.00148 μM | 24946214 | |||
| HCT15 | Growth inhibition assay | GI50 = 0.00151 μM | 24946214 | |||
| U251 | Growth inhibition assay | GI50 = 0.00155 μM | 24946214 | |||
| OVCAR5 | Growth inhibition assay | GI50 = 0.00155 μM | 24946214 | |||
| KM12 | Growth inhibition assay | GI50 = 0.0017 μM | 24946214 | |||
| SF295 | Growth inhibition assay | GI50 = 0.0017 μM | 24946214 | |||
| DU145 | Growth inhibition assay | GI50 = 0.0017 μM | 24946214 | |||
| HL-60(TB) | Growth inhibition assay | GI50 = 0.0019 μM | 24946214 | |||
| OVCAR4 | Growth inhibition assay | GI50 = 0.00195 μM | 24946214 | |||
| SNB19 | Growth inhibition assay | GI50 = 0.00204 μM | 24946214 | |||
| SNB75 | Growth inhibition assay | GI50 = 0.00204 μM | 24946214 | |||
| IGROV1 | Growth inhibition assay | GI50 = 0.00224 μM | 24946214 | |||
| OVCAR8 | Growth inhibition assay | GI50 = 0.00263 μM | 24946214 | |||
| PC3 | Growth inhibition assay | GI50 = 0.00263 μM | 24946214 | |||
| EKVX | Growth inhibition assay | GI50 = 0.00302 μM | 24946214 | |||
| A549/ATCC | Growth inhibition assay | GI50 = 0.00309 μM | 24946214 | |||
| HOP62 | Growth inhibition assay | GI50 = 0.00447 μM | 24946214 | |||
| NCI-H460 | Growth inhibition assay | GI50 = 0.00447 μM | 24946214 | |||
| K562 | Antiproliferative assay | 72 hrs | GI50 = 0.007 μM | 28441582 | ||
| NCI-ADR-RES | Growth inhibition assay | GI50 = 0.0123 μM | 24946214 | |||
| SKOV3 | Growth inhibition assay | GI50 = 0.0138 μM | 24946214 | |||
| NCI-H322M | Growth inhibition assay | GI50 = 0.0178 μM | 24946214 | |||
| DLD1 | Function assay | 6 hrs | IC50 = 0.0002 μM | 22206869 | ||
| DLD1 | Function assay | 6 hrs | IC50 = 0.0009 μM | 22206869 | ||
| HCT116 | Cytotoxicity assay | 72 hrs | IC50 = 0.001 μM | 28634039 | ||
| HCT116 | Antiproliferative assay | 72 hrs | IC50 = 0.0014 μM | 27769033 | ||
| HepG2 | Antiproliferative assay | 72 hrs | IC50 = 0.00161 μM | 27769033 | ||
| SKOV3 | Antiproliferative assay | 72 hrs | IC50 = 0.00162 μM | 27769033 | ||
| A2780 | Cytotoxicity assay | IC50 = 0.0017 μM | 18247547 | |||
| DOGUM | Cytotoxicity assay | 72 hrs | IC50 = 0.002 μM | 23031590 | ||
| U266 | Cytotoxicity assay | 72 hrs | IC50 = 0.00245 μM | 19537716 | ||
| A549 | Antiproliferative assay | 72 hrs | IC50 = 0.0025 μM | 28182990 | ||
| HL60 | Antiproliferative assay | 72 hrs | IC50 = 0.0032 μM | 28182990 | ||
| RPMI18226 | Cytotoxicity assay | 72 hrs | IC50 = 0.0035 μM | 21077681 | ||
| HL60 | Cytotoxicity assay | 72 hrs | IC50 = 0.0035 μM | 21077681 | ||
| RPMI8226 | Cytotoxicity assay | 72 hrs | IC50 = 0.00388 μM | 26965867 | ||
| HL60 | Function assay | 2 hrs | IC50 = 0.004 μM | 27769033 | ||
| U266 | Function assay | 1 hr | IC50 = 0.004 μM | 28441582 | ||
| HL60 | Function assay | 2 hrs | IC50 = 0.004 μM | 28634039 | ||
| SEM | Function assay | 2 hrs | IC50 = 0.00443 μM | 30365892 | ||
| HL60 | Cytotoxicity assay | 72 hrs | IC50 = 0.0055 μM | 19537716 | ||
| U266 | Cytotoxicity assay | 72 hrs | IC50 = 0.00573 μM | 26965867 | ||
| MGC803 | Antiproliferative assay | 72 hrs | IC50 = 0.005782 μM | 27769033 | ||
| GUMBUS | Cytotoxicity assay | 72 hrs | IC50 = 0.006 μM | 23031590 | ||
| ARH77 | Cytotoxicity assay | 72 hrs | IC50 = 0.00607 μM | 26965867 | ||
| SW480 | Cytotoxicity assay | 72 hrs | IC50 = 0.0061 μM | 20158184 | ||
| MDA-MB-231 | Antiproliferative assay | 72 hrs | IC50 = 0.0065 μM | 28182990 | ||
| HL60 | Function assay | 2 hrs | IC50 = 0.00667 μM | 30365892 | ||
| A549 | Cytotoxicity assay | 72 hrs | IC50 = 0.0067 μM | 20158184 | ||
| RPMI8226 | Antiproliferative assay | 72 hrs | IC50 = 0.0067 μM | 28182990 | ||
| 5TGM1 | Cytotoxicity assay | 48 to 72 hrs | IC50 = 0.00678 μM | 24119559 | ||
| HL60 | Cytotoxicity assay | 72 hrs | IC50 = 0.0069 μM | 19747832 | ||
| PC3 | Cytotoxicity assay | 72 hrs | IC50 = 0.007 μM | 20158184 | ||
| DOGUM | Cytotoxicity assay | 72 hrs | IC50 = 0.007 μM | 23031590 | ||
| HL60 | Cytotoxicity assay | 72 hrs | IC50 = 0.0071 μM | 20158184 | ||
| MKN45 | Antiproliferative assay | 72 hrs | IC50 = 0.00715 μM | 27769033 | ||
| HepG2 | Cytotoxicity assay | 72 hrs | IC50 = 0.0075 μM | 20158184 | ||
| HL60 | Antiproliferative assay | 72 hrs | IC50 = 0.0076 μM | 27769033 | ||
| RPMI8226 | Cytotoxic activity against human | 72 hrs | IC50 = 0.00796 μM | 24767818 | ||
| HL60 | Cytotoxicity assay | 72 hrs | IC50 = 0.008 μM | 28634039 | ||
| MGC803 | Cytotoxicity assay | 72 hrs | IC50 = 0.008 μM | 28634039 | ||
| SKOV3/TR | Function assay | 4 days | IC50 = 0.008 μM | 29767973 | ||
| PC3 | Cytotoxicity assay | 72 hrs | IC50 = 0.0083 μM | 21077681 | ||
| U266 | Cytotoxicity assay | 72 hrs | IC50 = 0.0088 μM | 20158184 | ||
| RPMI8226 | Cytotoxicity assay | IC50 = 0.0088 μM | 20727746 | |||
| RPMI8226 | Cytotoxicity assay | 48 to 72 hrs | IC50 = 0.0095 μM | 24119559 | ||
| ARH77 | Cytotoxicity assay | 72 hrs | IC50 = 0.00957 μM | 29934218 | ||
| HEK293 | Function assay | 3 hrs | IC50 = 0.01 μM | 20875739 | ||
| HCT116 | Cytotoxicity assay | 72 hrs | IC50 = 0.01 μM | 23547757 | ||
| NCI-H929 | Cytotoxicity assay | 72 hrs | IC50 = 0.01085 μM | 24767818 | ||
| CCRF-CEM | Antiproliferative assay | 72 hrs | IC50 = 0.011 μM | 26231162 | ||
| RPMI8226 | Cytotoxicity assay | 72 hrs | IC50 = 0.0112 μM | 29934218 | ||
| U266B1 | Cytotoxicity assay | 72 hrs | IC50 = 0.01163 μM | 29934218 | ||
| BxPC3 | Cytotoxicity assay | 72 hrs | IC50 = 0.0118 μM | 19747832 | ||
| 293T | Antiproliferative assay | 72 hrs | IC50 = 0.012 μM | 28191850 | ||
| U266 | Cytotoxicity assay | 72 hrs | IC50 = 0.0122 μM | 19747832 | ||
| SW480 | Cytotoxicity assay | 72 hrs | IC50 = 0.0123 μM | 21077681 | ||
| SKOV3 | Cytotoxicity assay | 4 days | IC50 = 0.0129 μM | 29767973 | ||
| A549 | Cytotoxicity assay | 72 hrs | IC50 = 0.0139 μM | 21077681 | ||
| HEK293 | Function assay | 30 mins | IC50 = 0.014 μM | 21044847 | ||
| RPMI8266 | Antiproliferative assay | 72 hrs | IC50 = 0.0144 μM | 26231162 | ||
| BxPC3 | Cytotoxicity assay | 72 hrs | IC50 = 0.0162 μM | 20158184 | ||
| MDA-MB-231 | Antiproliferative assay | 72 hrs | IC50 = 0.01665 μM | 27769033 | ||
| TOV21G | Antiproliferative assay | 72 hrs | IC50 = 0.0167 μM | 26231162 | ||
| MDA-MB-231 | Cytotoxicity assay | 72 hrs | IC50 = 0.017 μM | 28634039 | ||
| BxPC3 | Cytotoxicity assay | 72 hrs | IC50 = 0.0194 μM | 21077681 | ||
| HeLa | Growth inhibition assay | 72 hrs | IC50 = 0.02 μM | 19428245 | ||
| RKO | Antiproliferative assay | 72 hrs | IC50 = 0.0208 μM | 26231162 | ||
| MCF7 | Antiproliferative assay | 3 days | IC50 = 0.025 μM | 28557430 | ||
| Bel7404 | Antiproliferative assay | 72 hrs | IC50 = 0.02504 μM | 27769033 | ||
| HepG2 | Cytotoxicity assay | 72 hrs | IC50 = 0.0252 μM | 21077681 | ||
| HEK293 | Function assay | 24 hrs | IC50 = 0.027 μM | 21634429 | ||
| HCT116 | Antiproliferative assay | 72 hrs | IC50 = 0.027 μM | 26231162 | ||
| SUP-B15 | Function assay | 2 hrs | IC50 = 0.02809 μM | 30365892 | ||
| A431 | Antiproliferative assay | 72 hrs | IC50 = 0.0282 μM | 26231162 | ||
| A2780 | Antiproliferative assay | 72 hrs | IC50 = 0.0289 μM | 28182990 | ||
| HL60 | Function assay | 2 hrs | IC50 = 0.03 μM | 27769033 | ||
| HL60 | Function assay | 2 hrs | IC50 = 0.03 μM | 28634039 | ||
| HEK293 | Function assay | 6 hrs | IC50 = 0.03 μM | 28919340 | ||
| WM266.4 | Cytotoxicity assay | 72 hrs | IC50 = 0.035 μM | 22206869 | ||
| GUMBUS | Cytotoxicity assay | 72 hrs | IC50 = 0.035 μM | 23031590 | ||
| HepG2 | Cytotoxicity assay | 72 hrs | IC50 = 0.0375 μM | 19537716 | ||
| 95-D | Cytotoxicity assay | 72 hrs | IC50 = 0.038 μM | 28634039 | ||
| 95-D | Antiproliferative assay | 72 hrs | IC50 = 0.03818 μM | 27769033 | ||
| SW480 | Cytotoxicity assay | 72 hrs | IC50 = 0.05 μM | 19537716 | ||
| KB | Cytotoxicity assay | 72 hrs | IC50 = 0.0595 μM | 19537716 | ||
| SKOV3 | Cytotoxicity assay | 72 hrs | IC50 = 0.0668 μM | 21077681 | ||
| SW1990 | Antiproliferative assay | 72 hrs | IC50 = 0.07906 μM | 27769033 | ||
| HeLa | Cytotoxicity assay | 72 hrs | IC50 = 0.092 μM | 19537716 | ||
| A549 | Antiproliferative assay | 72 hrs | IC50 = 0.092 μM | 28191850 | ||
| H460 | Cytotoxicity assay | 72 hrs | IC50 = 0.115 μM | 19537716 | ||
| SKOV3 | Cytotoxicity assay | 72 hrs | IC50 = 0.13 μM | 19537716 | ||
| SKOV3 | Cytotoxicity assay | 72 hrs | IC50 = 0.151 μM | 20158184 | ||
| A549 | Cytotoxicity assay | 72 hrs | IC50 = 0.255 μM | 19537716 | ||
| HL60 | Function assay | 2 hrs | IC50 = 0.44 μM | 27769033 | ||
| HL60 | Function assay | 2 hrs | IC50 = 0.44 μM | 28634039 | ||
| H460 | Cytotoxicity assay | 72 hrs | IC50 = 0.78 μM | 20158184 | ||
| BGC823 | Cytotoxicity assay | 72 hrs | IC50 = 0.88 μM | 19537716 | ||
| MCF7 | Antiproliferative assay | 72 hrs | IC50 = 18.37 μM | 29426629 | ||
| A549 | Antiproliferative assay | 72 hrs | IC50 = 2.13573 μM | 27769033 | ||
| A549 | Cytotoxicity assay | 72 hrs | IC50 = 2.14 μM | 28634039 | ||
| BGC823 | Cytotoxicity assay | 72 hrs | IC50 = 2.89 μM | 19747832 | ||
| MDA-MB-231 | Antiproliferative assay | 72 hrs | IC50 = 3.125 μM | 29426629 | ||
| BCG823 | Cytotoxicity assay | 72 hrs | IC50 = 3.29 μM | 20158184 | ||
| A549 | Antiproliferative assay | 72 hrs | IC50 = 9.318 μM | 29426629 | ||
| Calu6 | Cytotoxicity assay | 72 hrs | LC50 = 0.0061 μM | 20875739 | ||
| HEK293T | Antiproliferative assay | 48 hrs | LC50 = 0.016 μM | 29843100 | ||
| LO2 | Antiproliferative assay | 48 hrs | LC50 = 0.398 μM | 29843100 | ||
| NCI-H929 | Cytotoxicity assay | 48 hrs | LD50 = 0.0066 μM | 27994734 | ||
| U266 | Cytotoxicity assay | 48 hrs | LD50 = 0.018 μM | 27994734 | ||
| LCL | Cytotoxicity assay | 48 hrs | LD50 = 0.02 μM | 27994734 | ||
| MDA-MB-468 | Cytotoxicity assay | 48 hrs | LD50 = 0.037 μM | 27994734 | ||
| RD-ES | Cytotoxicity assay | 48 hrs | LD50 = 0.04 μM | 27994734 | ||
| WE68 | Cytotoxicity assay | 48 hrs | LD50 = 0.1 μM | 27994734 | ||
| IMR90 | Cytotoxicity assay | 48 hrs | LD50 = 0.13 μM | 27994734 | ||
| KGN | Cytotoxicity assay | 48 hrs | LD50 = 0.18 μM | 27994734 | ||
| HNDF | Cytotoxicity assay | 48 hrs | LD50 = 0.48 μM | 27994734 | ||
| MCF10A | Cytotoxicity assay | 48 hrs | LD50 = 1.5 μM | 27994734 | ||
| SKOV3 | Cytotoxicity assay | 48 hrs | LD50 = 1.6 μM | 27994734 | ||
| MCF7 | Cytotoxicity assay | 48 hrs | LD50 = 9.8 μM | 27994734 | ||
| HL60 | Function assay | 100 nM | Inhibition of chymotrypsin-like activity of proteasome in human HL60 cells at 100 nM | 19655762 | ||
| HeLa | Function assay | 5 nM | 8 hrs | Inhibition of proteasome activity in human HeLa cells assessed as induction of ubiquitinG76V-FL reporter level at 5 nM after 8 hrs by luciferase assay | 21186794 | |
| HeLa | Function assay | 1 uM | 8 hrs | Inhibition of proteasome activity in human HeLa cells assessed as induction of ubiquitinG76V-FL reporter level at 1 uM after 8 hrs by luciferase assay | 21186794 | |
| LN229 | Function assay | 100 nM | 1 hr | Inhibition of HIF1alpha expression in human LN229 cells assessed as reduction of HIF-1alpha accumulation at 100 nM preincubated for 1 hr under normoxia condition followed by 24 hrs incubation under hypoxia condition by Western blotting | 21831638 | |
| LN229 | Function assay | 20 uM | 1 hr | Inhibition of hypoxia-induced HIF1alpha accumulation in human LN229 cells at 20 uM after 1 hr preincubation measured after 24 hrs by Western blot analysis | 22032632 | |
| U1 | Function assay | 10 uM | 24 hr | Inhibition of NF-kappaB-mediated viral replication in Homo sapiens (human) U1 cells infected with X4 tropic HIV1 NL4-3 at 10 uM after 24 hr by RT-PCR analysis in presence of TNF-alpha | 23290051 | |
| Calu6 | Function assay | 10 uM | 18 hrs | Inhibition of His-tagged Frataxin (unknown origin)/Ubiquitin interaction expressed in human Calu6 cells assessed as increase in frataxin (1-210) precursor level at 10 uM after 18 hrs by Western blotting analysis | 23506486 | |
| HCT116 | Function assay | Inhibition of proteasome in human HCT116 cells assessed as accumulation of p53 by Western blotting analysis | 23547757 | |||
| HCT116 | Apoptosis assay | Induction of apoptosis in human HCT116 cells assessed as induction of PARP cleavage by Western blotting analysis | 23547757 | |||
| HCT116 | Cell cycle assay | 24 hrs | Cell cycle arrest in human HCT116 cells assessed as accumulation at G2/M phase after 24 hrs by propidium iodide staining-based flow cytometric analysis | 23547757 | ||
| HEK293 | Cytotoxicity assay | 0.0001 uM to 100 uM | 48 hrs | Cytotoxicity against human HEK293 cells expressing murine FAP at 0.0001 uM to 100 uM after 48 hrs by CellTiter-Blue assay | 23594271 | |
| A549 | Function assay | 0.025 to 0.5 uM | 24 hrs | Induction of cell death in human A549 cells assessed as accumulation of poly-ubiquitinated proteins at 0.025 to 0.5 uM after 24 hrs by immunoblot assay | 25639862 | |
| A549 | Function assay | 0.025 to 0.5 uM | 24 hrs | Induction of cell death in human A549 cells assessed as stabilization of p53 at 0.025 to 0.5 uM after 24 hrs by immunoblot assay | 25639862 | |
| A549 | Function assay | 0.025 to 0.1 uM | 24 hrs | Induction of cell death in human A549 cells assessed as accumulation of Noxa at 0.025 to 0.1 uM after 24 hrs by immunoblot assay | 25639862 | |
| AMO1 | Antitumor assay | 1 mg/kg | Antitumor activity against human AMO1 cells xenografted in nude SCID beige mouse assessed as tumor growth inhibition at 1 mg/kg, iv administered twice per week | 26565666 | ||
| MCF7 | Function assay | 35 nM | 4 hrs | Inhibition of 26S proteasome in human MCF7 cells assessed as accumulation of high molecular weight polyubiquitin-conjugated proteins at 35 nM after 4 hrs by Western blot analysis | 27994734 | |
| MDA-MB-468 | Function assay | 35 nM | 4 hrs | Inhibition of 26S proteasome in human MDA-MB-468 cells assessed as accumulation of high molecular weight polyubiquitin-conjugated proteins at 35 nM after 4 hrs by Western blot analysis | 27994734 | |
| MDA-MB-231 | Function assay | 1 uM | Inhibition of trypsin like activity of 26S proteasome derived from human MDA-MB-231 cells at 1 uM | 28291344 | ||
| MDA-MB-231 | Function assay | 1 uM | Inhibition of caspase like activity of 26S proteasome derived from human MDA-MB-231 cells at 1 uM | 28291344 | ||
| MDA-MB-231 | Function assay | 1 uM | Inhibition of chymotrypsin like activity of 26S proteasome derived from human MDA-MB-231 cells at 1 uM | 28291344 | ||
| SK-N-SH | Cytotoxicity assay | 0.1 to 1 uM | 24 hrs | Cytotoxicity against human SK-N-SH cells assessed as reduction in cell viability at 0.1 to 1 uM after 24 hrs by MTT assay | 29269255 | |
| MYCN2 | Cytotoxicity assay | 0.1 to 1 uM | 24 hrs | Cytotoxicity against human MYCN2 cells assessed as reduction in cell viability at 0.1 to 1 uM after 24 hrs by MTT assay | 29269255 | |
| U266 | Apoptosis assay | 2.5 nM | 24 hrs | Induction of apoptosis in human U266 cells at 2.5 nM after 24 hrs by Annexin V/propidium iodide staining based flow cytometry | 29304284 | |
| RPMI8226 | Apoptosis assay | 2.5 nM | 24 hrs | Induction of apoptosis in human RPMI8226 cells at 2.5 nM after 24 hrs by Annexin V/propidium iodide staining based flow cytometry | 29304284 | |
| NCI-H929 | Apoptosis assay | 2.5 nM | 24 hrs | Induction of apoptosis in human NCI-H929 cells at 2.5 nM after 24 hrs by Annexin V/propidium iodide staining based flow cytometry | 29304284 | |
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 29435139 | |||
| U-2 OS | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 29435139 | |||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | |||
| DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 29435139 | |||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | |||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | |||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 29435139 | |||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | |||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 29435139 | |||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 29435139 | |||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 29435139 | |||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | |||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells | 29435139 | |||
| fibroblast | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 29435139 | |||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells | 29435139 | |||
| DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells | 29435139 | |||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells | 29435139 | |||
| Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 29435139 | |||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells | 29435139 | |||
| Rh30 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 29435139 | |||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) | 29435139 | |||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells | 29435139 | |||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells | 29435139 | |||
| Rh30 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells | 29435139 | |||
| fibroblast | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells | 29435139 | |||
| U-2 OS | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells | 29435139 | |||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells | 29435139 | |||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SK-N-SH cells | 29435139 | |||
| Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells | 29435139 | |||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells | 29435139 | |||
| Daoy | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for Daoy cells | 29435139 | |||
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D caspase screen for TC32 cells | 29435139 | |||
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for TC32 cells | 29435139 | |||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for MG 63 (6-TG R) cells | 29435139 | |||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | |||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | |||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | |||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | |||
| Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 29435139 | |||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells | 29435139 | |||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells | 29435139 | |||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells | 29435139 | |||
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells | 29435139 | |||
| Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells | 29435139 | |||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells | 29435139 | |||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells | 29435139 | |||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for RD cells | 29435139 | |||
| HL60 | Function assay | 1 to 100 nM | 24 hrs | Inhibition of proteasome in human HL60 cells assessed as increase in cleaved PARP expression at 1 to 100 nM after 24 hrs by immunoblot assay | 30365892 | |
| SUP-B15 | Function assay | 1 to 100 nM | 24 hrs | Inhibition of proteasome in imatinib-resistant human SUP-B15 cells assessed as increase in cleaved PARP expression at 1 to 100 nM after 24 hrs by immunoblot assay | 30365892 | |
| SEM | Function assay | 1 to 100 nM | 24 hrs | Inhibition of proteasome in human SEM cells assessed as increase in cleaved PARP expression at 1 to 100 nM after 24 hrs by immunoblot assay | 30365892 | |
| SEM | Function assay | 10 nM | 18 hrs | Inhibition of proteasome in human SEM cells assessed as increase in aggresome accumulation at 10 nM after 18 hrs by by FACS analysis | 30365892 | |
| SEM | Function assay | 10 nM | 18 hrs | Inhibition of proteasome in human SEM cells assessed as increase in aggresome accumulation at 10 nM after 18 hrs by fluorescence microscopic method | 30365892 | |
| HepG2 | Cell viability assay | HepG2 cells viability qHTS for Zika virus inhibitors | 33229545 | |||
| Cliquez pour voir plus de données expérimentales sur la lignée cellulaire | ||||||
| Poids moléculaire | 384.24 | Formule | C19H25BN4O4 |
Stockage (À compter de la date de réception) | 3 years-20°C (in the dark)powder |
|---|---|---|---|---|---|
| N° CAS | 179324-69-7 | Télécharger le SDF | Stockage des solutions mères |
|
|
| Synonymes | LDP-341, MLM341, NSC 681239,PS-341, BTZ | Smiles | B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O | ||
|
In vitro |
DMSO
: 77 mg/mL
(200.39 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Étape 1 : Saisir les informations ci-dessous (Recommandé : Un animal supplémentaire pour tenir compte des pertes pendant lexpérience)
Étape 2 : Saisir la formulation in vivo (Ceci est seulement le calculateur, pas la formulation. Veuillez nous contacter dabord sil ny a pas de formulation in vivo dans la section Solubilité.)
Résultats du calcul :
Concentration de travail : mg/ml;
Méthode de préparation du liquide maître DMSO : mg médicament prédissous dans μL DMSO ( Concentration du liquide maître mg/mL, Veuillez nous contacter dabord si la concentration dépasse la solubilité du DMSO du lot de médicament. )
Méthode de préparation de la formulation in vivo : Prendre μL DMSO liquide maître, puis ajouterμL PEG300, mélanger et clarifier, puis ajouterμL Tween 80, mélanger et clarifier, puis ajouter μL ddH2O, mélanger et clarifier.
Méthode de préparation de la formulation in vivo : Prendre μL DMSO liquide maître, puis ajouter μL Huile de maïs, mélanger et clarifier.
Note : 1. Veuillez vous assurer que le liquide est clair avant dajouter le solvant suivant.
2. Assurez-vous dajouter le(s) solvant(s) dans lordre. Vous devez vous assurer que la solution obtenue, lors de lajout précédent, est une solution claire avant de procéder à lajout du solvant suivant. Des méthodes physiques telles que le vortex, les ultrasons ou le bain-marie chaud peuvent être utilisées pour faciliter la dissolution.
| Targets/IC50/Ki |
NF-κB
20S proteasome
(Cell-free assay) 0.6 nM(Ki)
|
|---|---|
| In vitro |
Bortezomib, un dipeptide d'acide boronique, est un inhibiteur hautement sélectif et réversible du 26S Proteasome qui fonctionne principalement dans la dégradation des protéines mal repliées et est essentiel pour la régulation du cycle cellulaire. L'exposition à ce composé a montré qu'elle stabilise p21, p27 et p53, ainsi que les protéines proapoptotiques Bid et Bax, la cavéoline-1 et l'inhibiteur κB-α, ce qui empêche l'activation des voies de survie cellulaire induites par le facteur nucléaire κB. Il favorise également l'activation de la c-Jun-NH2 terminal kinase proapoptotique, ainsi que la réponse au stress du réticulum endoplasmique. L'altération des niveaux de ces protéines cellulaires conduit à l'inhibition de la prolifération, de la migration et à la promotion de l'apoptose des cellules cancéreuses. Ce produit chimique est démontré pénétrer dans les cellules et inhiber la protéolyse intracellulaire des protéines à longue durée de vie médiée par le Proteasome, avec une concentration qui inhibe 50% de la protéolyse d'environ 0,1 μM. La valeur moyenne d'inhibition de croissance de 50% pour ce composé sur l'ensemble des 60 lignées de cellules cancéreuses dérivées de multiples tumeurs humaines de l'US National Cancer Institute (NCI) est de 7 nM. Le traitement des cellules PC-3 avec celui-ci (100 nM) pendant 8 h entraîne l'accumulation de cellules en G2-M, avec une diminution correspondante du nombre de cellules en G1. Il tue les cellules PC-3 à 24 et 48 h avec une IC50 de 100 et 20 nM, respectivement. Cet agent induit une condensation nucléaire 16 à 24 h après le traitement. Son traitement entraîne le clivage de PARP de manière dépendante du temps avec des concentrations aussi faibles que 100 nM étant efficaces à 24 h. |
| Essai kinase |
Méthodes cinétiques
|
|
Dans une analyse cinétique typique, 2,00 mL de tampon de dosage (20 mM HEPES, 0,5 mM EDTA, 0,035 % SDS, pH 7,8) et de Suc-Leu-Leu-Val-Tyr-AMC dans du DMSO sont ajoutés à une cuvette de fluorescence de 3 mL, et la cuvette est placée dans le support de cellule à enveloppe d'un spectrophotomètre de fluorescence. La température de réaction est maintenue à 37 ℃ par un bain-marie à circulation. Une fois que la solution de réaction a atteint l'équilibre thermique (5 minutes), 1 μL à 10 μL de la solution enzymatique mère est ajoutée à la cuvette. La progression de la réaction est surveillée par l'augmentation de l'émission de fluorescence à 440 nm (λex= 380 nm) qui accompagne le clivage de l'AMC des substrats peptide-AMC.
|
|
| In vivo |
Les effets anticancéreux de Bortezomib en monothérapie ont été démontrés dans des modèles xénogreffes de myélome multiple, de leucémie à cellules T adultes, de cancers du poumon, du sein, de la prostate, du pancréas, de la tête et du cou, et du côlon, ainsi que dans le mélanome. L'administration orale de ce composé à 1,0 mg/kg par jour pendant 18 jours entraîne des retards de croissance tumorale, ainsi qu'une diminution du nombre de métastases dans le modèle de cancer du poumon de Lewis. Ce composé à une dose unique allant jusqu'à 5 mg/kg a significativement diminué la fraction survivante des cellules tumorales mammaires. L'administration hebdomadaire de ce produit chimique à 1,0 mg/kg pendant 4 semaines réduit la croissance tumorale de 60 % dans des modèles xénogreffes murins de cancer de la prostate. Le traitement avec cet agent à 1,0 mg/kg pendant 4 semaines entraîne une réduction de 72 % ou 84 % de la croissance des xénogreffes murines de cancer du pancréas, ainsi qu'une augmentation de l'apoptose des cellules tumorales. Ce composé à 1,0 mg/kg entraîne une inhibition significative de la croissance des xénogreffes de plasmacytome humain, une augmentation de l'apoptose des cellules tumorales et de la survie globale, et une diminution de l'angiogenèse tumorale. |
Références |
|
| Méthodes | Biomarqueurs | Images | PMID |
|---|---|---|---|
| Western blot | phospho-PERK / ATF-4 GRP-78 / GADD-34 pro-caspase-12 / pro-caspase-3 pro-caspase-9 p-IκBα / IκBα COX-2 / cIAP2 |
|
15509775 |
| Immunofluorescence | Vimentin Ubiquitin |
|
19010849 |
| Growth inhibition assay | Cell viability |
|
20571067 |
| ELISA | IL-8 |
|
24085292 |
(données du https://clinicaltrials.gov, mis à jour le 2024-05-22)
| Numéro NCT | Recrutement | Conditions | Promoteur/Collaborateurs | Date de début | Phases |
|---|---|---|---|---|---|
| NCT05599880 | Recruiting | Relapsed/Refractory Immune Thrombocytopenia |
Seoul National University Hospital |
July 7 2023 | Phase 2 |
| NCT05781425 | Recruiting | Chemotherapy-induced Peripheral Neuropathy |
Odense University Hospital|Aarhus University Hospital|Sygehus Lillebaelt|University of Southern Denmark |
May 12 2023 | -- |
| NCT05383547 | Unknown status | Bortezomib|Glomerulonephritis|MN|MPGN|FSGS|IgA Nephropathy |
Ruijin Hospital |
August 2 2022 | Not Applicable |
| NCT04915248 | Recruiting | Plasmablastic Lymphoma |
Fondazione Italiana Linfomi - ETS|Janssen-Cilag S.p.A. |
July 11 2022 | Phase 2 |
| NCT04656951 | Recruiting | Multiple Myeloma |
University of Cologne|Janssen-Cilag G.m.b.H |
June 1 2021 | Phase 2 |
Tel: +1-832-582-8158 Ext:3
Si vous avez dautres questions, veuillez laisser un message.
Question 1:
On your website, it is mentioned that it should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?
Réponse :
S1013 This compound in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve it in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.